Free Trial

Creative Medical Technology Q3 2023 Earnings Report

Creative Medical Technology logo
$2.07 +0.07 (+3.50%)
(As of 12/20/2024 05:51 PM ET)

Creative Medical Technology EPS Results

Actual EPS
-$1.02
Consensus EPS
-$0.86
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Creative Medical Technology Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Creative Medical Technology Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

This Indicator called BOTH NVDA rallies (Ad)

Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Click this link here. 

Creative Medical Technology Earnings Headlines

Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
See More Creative Medical Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Creative Medical Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Creative Medical Technology and other key companies, straight to your email.

About Creative Medical Technology

Creative Medical Technology (NASDAQ:CELZ), a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

View Creative Medical Technology Profile

More Earnings Resources from MarketBeat

Upcoming Earnings